SAN DIEGO, June 17, 2015 /PRNewswire/ -- Organovo
Holdings, Inc. (NYSE MKT: ONVO) ("Organovo") today announced that
it has commenced an underwritten public offering of shares of its
common stock. The offering is subject to market and other
conditions, and there can be no assurance as to whether or when the
offering may be completed, or as to the actual size or terms of the
offering.
Jefferies LLC and Piper Jaffray
& Co. are acting as joint book-running managers for the
offering.
The shares described above will be offered pursuant to a shelf
registration statement on Form S-3 previously filed with and
declared effective by the Securities and Exchange Commission
("SEC"). Organovo intends to file a preliminary prospectus
supplement relating to the offering with the SEC, which will be
available on the SEC's website at www.sec.gov. Copies of the
preliminary prospectus supplement and the accompanying prospectus
may be obtained by sending a request to: Jefferies LLC,
Attention: Equity Syndicate Prospectus Department, 520 Madison
Avenue, 12th Floor, New York, New
York 10022, by telephone at 877-547-6340, or by email at
Prospectus_Department@Jefferies.com; or Piper Jaffray & Co., Attention: Prospectus
Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by telephone at
800-503-4611, or by e-mailing prospectus@pjc.com.
This press release does not constitute an offer to sell or a
solicitation of an offer to buy any securities of Organovo, nor
shall there be any sale of securities in any state or jurisdiction
in which such an offer, solicitation or sale would be unlawful
prior to registration or qualification under the securities laws of
any such state or jurisdiction. This press release is being issued
pursuant to and in accordance with Rule 134 under the Securities
Act of 1933, as amended.
About Organovo Holdings, Inc.
Organovo designs and creates functional, three-dimensional human
tissues for medical research and therapeutic applications. The
Company develops 3D human disease models through internal
development and in collaboration with pharmaceutical and academic
partners. Organovo believes these 3D human tissues have the
potential to accelerate the drug discovery process, enabling
treatments to be developed faster and at lower cost.
Safe Harbor Statement
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements as that
term is defined in the Private Securities Litigation Reform Act of
1995. Any forward-looking statements contained herein are based on
the Company's current expectations, but are subject to a number of
risks and uncertainties. The factors that could cause the Company's
actual future results to differ materially from current
expectations include, but are not limited to, risks and
uncertainties relating to the ability to complete the proposed
offering; risks and uncertainties relating to the Company's ability
to develop, market and sell products based on its technology; the
expected benefits and efficacy of the Company's products and
technology; the market acceptance of the Company's products; the
Company's business, research, product development, regulatory
approval, marketing and distribution plans and strategies; and the
Company's ability to successfully complete the contracts and
recognize the revenue represented by the contracts included in its
previously reported total contract bookings. These and other
factors are identified and described in more detail in the
Company's filings with the SEC, including its annual report on Form
10-K filed with the SEC on June 9,
2015, its preliminary prospectus supplement to be filed with
the SEC and its other filings with the SEC. You should not place
undue reliance on these forward-looking statements, which speak
only as of the date that they were made. These cautionary
statements should be considered with any written or oral
forward-looking statements that we may issue in the future. Except
as required by applicable law, including the securities laws of
the United States, we do not
intend to update any of the forward-looking statements to conform
these statements to reflect actual results, later events or
circumstances or to reflect the occurrence of unanticipated
events.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/organovo-holdings-inc-announces-proposed-public-offering-of-common-stock-300100963.html
SOURCE Organovo Holdings, Inc.